Nelson Dusetti: A key step forward in Organoid-Based Drug Screening
Nelson Dusetti, Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM, shared an article on LinkedIn:
“I am thrilled to share the publication of a collaborative work with our partners at the University of Antwerp and Antwerp University Hospital.
This study represents a key step forward in organoid-based drug screening, introducing the Normalized Organoid Growth Rate (NOGR) metric, which significantly enhances our ability to differentiate between cytostatic and cytotoxic effects in drug response studies.
By integrating advanced label-free image analysis, this work improves the accuracy of drug sensitivity assessments, paving the way for more effective personalized treatment strategies.
I am very proud to have contributed to this important research, which strengthens the bridge between innovative methodologies and clinical applications in oncology. These advancements make organoid-based screenings not only more precise but also more accessible to researchers worldwide.
A huge congratulations to Christophe Deben the entire team for this achievement.”
Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays.
Authors: Christophe Deben, et al.
Nelson Dusetti is the Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023